Evidence map›Paper›PMID 38512652›Full record

ArticleInflammopharmacology2024

Neuroprotective effects of rutin against cuprizone-induced multiple sclerosis in mice.

Mariam A Nicola, Abdelraheim H Attaai, Mahmoud H Abdel-Raheem, Anber F Mohammed, Yasmin F Abu-Elhassan

Open access · hybridAbstract read
In one paragraph

Article in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Berberine-loaded iron oxide nanoparticles alleviate cuprizone-induced astrocytic reactivity in a rat model of multiple sclerosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mariam A NicolaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Asyût, 71526, Egypt. mariampharmacology@aun.edu.eg.ORCID http://orcid.org/0000-0002-8612-640X
Abdelraheim H AttaaiDepartment of Anatomy and Histology, School of Veterinary Medicine, Badr University in Assiut, New Nasser City, West of Assiut, Asyût, Egypt.ORCID http://orcid.org/0000-0001-8481-2687
Mahmoud H Abdel-RaheemDepartment of Pharmacology, Faculty of Medicine, Assiut University, Asyût, Egypt.
Anber F MohammedDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Asyût, 71526, Egypt.ORCID http://orcid.org/0000-0002-4005-982X
Yasmin F Abu-ElhassanDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Asyût, 71526, Egypt.
Assiut University · EGBadr University in Cairo · EG

Funding

Assiut Medical school grants office, Assiut University, Assiut, Egypt 2022-07-04-008
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system that injures the myelin sheath, provoking progressive axonal degeneration and functional impairments. No efficient therapy is available at present to combat such insults, and hence, novel safe and effective alternatives for MS therapy are extremely required. Rutin (RUT) is a flavonoid that exhibits antioxidant, anti-inflammatory, and neuroprotective effects in several brain injuries. The present study evaluated the potential beneficial effects of two doses of RUT in a model of pattern-III lesion of MS, in comparison to the conventional standard drug; dimethyl fumarate (DMF). Demyelination was induced in in male adult C57BL/6 mice by dietary 0.2% (w/w) cuprizone (CPZ) feeding for 6 consecutive weeks. Treated groups received either oral RUT (50 or 100 mg/kg) or DMF (15 mg/kg), along with CPZ feeding, for 6 consecutive weeks. Mice were then tested for behavioral changes, followed by biochemical analyses and histological examinations of the corpus callosum (CC). Results revealed that CPZ caused motor dysfunction, demyelination, and glial activation in demyelinated lesions, as well as significant oxidative stress, and proinflammatory cytokine elevation. Six weeks of RUT treatment significantly improved locomotor activity and motor coordination. Moreover, RUT considerably improved remyelination in the CC of CPZ + RUT-treated mice, as revealed by luxol fast blue staining and transmission electron microscopy. Rutin also significantly attenuated CPZ-induced oxidative stress and inflammation in the CC of tested animals. The effect of RUT100 was obviously more marked than either that of DMF, regarding most of the tested parameters, or even its smaller tested dose. In silico docking revealed that RUT binds tightly within NF-κB at the binding site of the protein-DNA complex, with a good negative score of -6.79 kcal/mol. Also, RUT-Kelch-like ECH-associated protein 1 (Keap1) model clarifies the possible inhibition of Keap1-Nrf2 protein-protein interaction. Findings of the current study provide evidence for the protective effect of RUT in CPZ-induced demyelination and behavioral dysfunction in mice, possibly by modulating NF-κB and Nrf2 signaling pathways. The present study may be one of the first to indicate a pro-remyelinating effect for RUT, which might represent a potential additive benefit in treating MS.

Indexed as

Demyelinating DiseasesMultiple SclerosisNeurodegenerative DiseasesNeuroprotective AgentsAnimalsCuprizoneDisease Models, AnimalKelch-Like ECH-Associated Protein 1MaleMiceMice, Inbred C57BLNF-E2-Related Factor 2NF-kappa BRutinCuprizoneKelch-Like ECH-Associated Protein 1Neuroprotective AgentsNF-E2-Related Factor 2NF-kappa BRutinAnti-inflammatoryAntioxidantCuprizoneMultiple sclerosisRutin

Identifiers

PMID38512652
PMCPMC11006763
OpenAlexW4393044872

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.